Baricitinib: BDR Pharma signs licensing agreement with Lilly

Lilly received permission for restricted emergency use from the Central Drugs Standard Control Organization, a division of the Ministry of Health.

Picture: Pixabay

BDR Pharma has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company, for the manufacturing and distribution of baricitinib for the treatment of C-19 in India.

Baricitinib received restricted emergency use approval, for use in combination with remdesivir, for treatment of suspected or laboratory-confirmed coronavirus disease 2019 (C-19) in hospitalized adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Medicine Tablet
Picture: Pixabay

Lilly received permission for restricted emergency use from the Central Drugs Standard Control Organization (CDSCO), a division of the Ministry of Health.

“We are swiftly working to ensure high-quality manufacturing and equitable access of Baricitinib for C-19 in India. We will continue to explore other possible initiatives to support patients and the healthcare system in India.” – Luca Visini, MD, India Subcontinent, Lilly India

Commenting on the development and the royalty-free non-exclusive voluntary license with Lilly, Dharmesh Shah, Chairman, BDR Pharmaceuticals, said, “We hope this collaboration will address more unmet medical needs by broadening and deepening the discovery and development of C-19 treatments options.”

BDR has applied for restricted emergency use approval with the Drug Controller General of India (DCGI) for baricitinib for C-19 in India. Lilly had recently announced seven voluntary license agreements with major local generic drug manufacturers in India for the production of the same.

Also read:

Two held for selling drugs in black market

NPPA directs Pulse Oximeter & Oxygen Concentrators to submit MRP

Black Fungus: AIIMS to develop Guidelines for treatment

DTAB dismisses proposal on labeling of drugs non-vegetarian origin with red…

DRDO launches anti-C-19 drug 2-DG

Home care package for C-19 patients launched

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner